Stay updated on Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Sign up to get notified when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.

Latest updates to the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page
- Check7 days agoChange DetectedA new revision v3.4.2 was added to the history, replacing the previous v3.4.1.SummaryDifference0.1%

- Check14 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 in the page history; no visible changes to study details or content.SummaryDifference0.1%

- Check21 days agoNo Change Detected
- Check36 days agoChange DetectedAdded Revision: v3.3.4 and removed Revision: v3.3.3 from the page's revision history.SummaryDifference0.1%

- Check58 days agoChange DetectedRevision: v3.3.3 has been added to the history, and HHS Vulnerability Disclosure and Revision: v3.3.2 have been removed from the page footer. These updates reflect minor metadata changes to the page's revision history.SummaryDifference0.1%

- Check87 days agoChange DetectedRevision: v3.3.2 appears as the site revision tag, replacing v3.2.0. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check94 days agoChange DetectedThe general government funding notice about operating status was removed; otherwise the study record history content remains unchanged. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.5%

Stay in the know with updates to Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Durvalumab Safety Post Chemo Radiation in Stage III NSCLC Clinical Trial page.